Skip to main content
. 2020 Jun 10;155(7):572–579. doi: 10.1001/jamasurg.2020.1133

Figure 4. Expression Levels and Diagnostic Values of Gastric Cancer (GC)–Associated Long Noncoding RNA1 (lncRNA-GC1), Carcinoembryonic Antigen (CEA), Cancer Antigen 72-4 (CA72-4), and CA19-9 in the Total Phase (Test and Verification).

Figure 4.

A, The relative levels of circulating exosomal lncRNA-GC1 in patients with GC (n = 482), patients with early gastric cancer (EGC) (n = 217), patients with chronic atrophic gastritis (CAG) (n = 37), patients with intestinal metaplasia (IM) (n = 48), and healthy donor individuals (HDs) (n = 219). B, Receiver operating characteristic curves of lncRNA-GC1, CEA, CA72-4, and CA19-9 in distinguishing EGC from HD. C, Receiver operating characteristic curves of lncRNA-GC1 in distinguishing patients with EGC with negative status of CEA, CA72-4, and CA19-9 from HD. D, Differential expression of circulating exosomal lncRNA-GC1 between patients with GC before surgery and 5 days after surgery in the supplemental phase. The results are presented as mean (SD).

aP < .001.